Karo Pharma AB (publ)

OM:KARO Stok Raporu

Piyasa değeri: SEK 16.6b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Karo Pharma Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Christoffer Lorenzen

İcra Kurulu Başkanı

SEK 12.6m

Toplam tazminat

CEO maaş yüzdesi35.8%
CEO görev süresi3.3yrs
CEO sahipliğin/a
Yönetim ortalama görev süresi2.2yrs
Yönetim Kurulu ortalama görev süresi2.5yrs

Son yönetim güncellemeleri

Recent updates

Karo Pharma (STO:KARO) Has No Shortage Of Debt

Oct 14
Karo Pharma (STO:KARO) Has No Shortage Of Debt

Is Karo Pharma (STO:KARO) A Risky Investment?

Jul 10
Is Karo Pharma (STO:KARO) A Risky Investment?

Karo Pharma (STO:KARO) Seems To Be Using A Lot Of Debt

Mar 23
Karo Pharma (STO:KARO) Seems To Be Using A Lot Of Debt

Karo Pharma's (STO:KARO) Strong Earnings Are Of Good Quality

Feb 24
Karo Pharma's (STO:KARO) Strong Earnings Are Of Good Quality

Is Karo Pharma AB (publ)'s (STO:KARO) 1.5% ROE Worse Than Average?

Feb 22
Is Karo Pharma AB (publ)'s (STO:KARO) 1.5% ROE Worse Than Average?

Did You Participate In Any Of Karo Pharma's (STO:KARO) Fantastic 144% Return ?

Feb 01
Did You Participate In Any Of Karo Pharma's (STO:KARO) Fantastic 144% Return ?

CEO Tazminat Analizi

Christoffer Lorenzen'un ücretlendirmesi Karo Pharma'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2022n/an/a

-SEK 190m

Mar 31 2022n/an/a

-SEK 141m

Dec 31 2021SEK 13mSEK 5m

-SEK 17m

Sep 30 2021n/an/a

SEK 63m

Jun 30 2021n/an/a

SEK 2m

Mar 31 2021n/an/a

SEK 49m

Dec 31 2020SEK 12mSEK 5m

SEK 82m

Sep 30 2020n/an/a

SEK 86m

Jun 30 2020n/an/a

SEK 87m

Mar 31 2020n/an/a

SEK 55m

Dec 31 2019SEK 16mSEK 2m

SEK 9m

Tazminat ve Piyasa: Christoffer's total compensation ($USD1.20M) is above average for companies of similar size in the Swedish market ($USD901.38K).

Tazminat ve Kazançlar: Christoffer's compensation has increased whilst the company is unprofitable.

CEO

Christoffer Lorenzen (47 yo)

3.3yrs

Görev süresi

SEK 12,564,000

Tazminat

Mr. Christoffer Lorenzen has been the Chief Executive Officer of Karo Pharma AB since July 1, 2019. Mr. Lorenzen was an Executive Vice President of Food Cultures & Enzymes at Chr. Hansen Holding A/S from A...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Christoffer Lorenzen
Chief Executive Officer3.3yrsSEK 12.56mVeri yok
Jon Johnsson
Chief Financial Officer3.1yrsVeri yokVeri yok
Jonathan Kimber
Vice President of Operations3.2yrsVeri yokVeri yok
Sofia Kyhlstedt
Vice President of Scientific Affairsno dataVeri yokVeri yok
Lisa Westerdahl
VP of Commercial Pharma Operations & Corporate Communicationsno dataVeri yokVeri yok
Anna Hale
Chief Marketing Officer1.8yrsVeri yokVeri yok
Karin Lindberg
Head of People & Organization2.5yrsVeri yokVeri yok
SIMON Nyberg-Hansen
Managing Director of Norwayno dataVeri yokVeri yok
Fredrik Thorsen
Head of Digital & E-commerce1.5yrsVeri yokVeri yok
Matt Roberts
Chief Commercial Officer1.2yrsVeri yokVeri yok
Robin List
Chief Executive Officer of Sylpharless than a yearVeri yokVeri yok
Anna Elmblad
Vice President of Digital Marketingno dataVeri yokVeri yok

2.2yrs

Ortalama Görev Süresi

47yo

Ortalama Yaş

Deneyimli Yönetim: KARO's management team is considered experienced (2.2 years average tenure).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Mark Keatley
Independent Director1.6yrsSEK 413.00kVeri yok
Uta Kemmerich-Keil
Independent Director2.5yrsSEK 394.00kVeri yok
Erika Henriksson
Director3.8yrsSEK 394.00kVeri yok
Flemming Ørnskov
Independent Director3.1yrsSEK 394.00kVeri yok
Kristofer Tonström
Independent Director2.5yrsSEK 394.00kVeri yok
Patrick Smallcombe
Independent Chairman1.6yrsSEK 552.00kVeri yok
Claire Hennah
Independent Directorless than a yearVeri yokVeri yok

2.5yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: KARO's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.